The United States of America, As Represented by the Secretary, Department of Health and Human Services

Brian H Bird

Stuart T Nichol

Cesar G Albarino

Thomas G Ksiazek

Kimberly A Dodd

Described herein are recombinant RVF viruses comprising deletions in one or more viral virulence genes, such as NSs and NSm. The recombinant RVF viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent infection of RVF virus in livestock and humans. As described herein, the recombinant RVF viruses grow to high titers, provide protective immunity following a single injection and allow for the differentiation between vaccinated animals and animals infected with wild-type RVF virus.

Recombinant rift valley fever (RVF) viruses and methods of use

Disclosed herein is a robust system for the reverse genetics generation of a Rift Valley fever (RVF) virus replicon particle (VRP) vaccine candidate. VRPcan actively synthesize viral RNA and proteins, but lack structural glycoprotein genes, preventing spread within immunized individuals and reducing the risk of vaccine-induced pathogenicity. Is it disclosed herein that VRPimmunization is both safe and efficacious, resulting in a robust immune response that is protective against RVF virus challenge within 24 hours of immunization. Provided herein are VRP, methods of producing VRP, and method of using VRPfor immunization against RVF virus infection.

Rift valley fever virus replicon particles and use thereof

Recombinant rift valley fever (RVF) viruses and methods

Recombinant Rift Valley fever (RVF) viruses and methods of use

Growing community of inventors

Atlanta, GA, United States of America

Brian H Bird